In his weekly clinical update, Dr. Griffin discusses a molnupiravir-associated mutational signature in global SARS-CoV-2 genomes, inhaled fluticasone furoate for outpatient treatment of COVID-19, optimal duration of systemic corticosteroids in COVID-19 treatment, early antibody treatment, inflammation, and risk of post-COVID conditions, autonomic dysregulation in long-term patients suffering from post-COVID-19 syndrome assessed by heart rate variability, and multiorgan MRI findings after hospitalization with COVID-19 in the UK.
Click arrow to play
Download TWiV 1048 (32 MB .mp3, 45 min)
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode
- Molnupiravir-associated mutational signature in global SARS-CoV-2 genomes (Nature) 9:46
- Inhaled fluticasone furoate for outpatient treatment of COVID-19 (NEJM) 13:41
- Optimal duration of systemic corticosteroids in COVID-19 treatment (OFID)
- Distinguishing features of Long COVID identified through immune profiling (Nature) 6:11
- Early antibody treatment, inflammation, and risk of post-COVID conditions (mBIO) 29:14
- Autonomic dysregulation in long-term patients suffering from post COVID-19 syndrome (SR) 30:47
- Multiorgan MRI findings after hospitalization with COVID-19 in the UK (The Lancet) 33:07
- Contribute to our Floating Doctors fundraiser at PWB 35:44
- Letters read on TWiV 1048 36:13
- Dr. Griffin’s COVID treatment summary (pdf)
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees
Send your questions for Dr. Griffin to daniel@microbe.tv
Leave a Reply